Literature DB >> 7682604

Norepinephrine suppresses inducible nitric oxide synthase activity in rat astroglial cultures.

D L Feinstein1, E Galea, D J Reis.   

Abstract

Exposure of primary rat astrocyte cultures to bacterial endotoxin lipopolysaccharide (LPS) causes expression of a Ca(2+)-independent form of nitric oxide synthase (NOS). In these cells, the presence of norepinephrine (NE) caused a dose-dependent inhibition of the LPS induction of NOS activity, with an IC50 value of 100 nM and significant suppression at 100 pM. Short incubations (5-40 min) with NE were as effective as 24-h continuous exposure, and inhibition was observed up to the longest incubation period measured (56 h). In contrast, previously induced NOS activity was not affected by exposure to NE. The effects of NE were mediated primarily by binding to beta-adrenergic receptors (beta-ARs) because (a) the beta-AR antagonist propranolol, but not the alpha-AR antagonist phentolamine, could reverse the effects of NE; (b) the beta-AR agonist isoproterenol, but not the alpha-AR agonist phenylephrine, was as effective as NE in blocking the effects of LPS; and (c) incubation with the cyclic AMP analogue dibutyryl cyclic AMP replicated the effects of NE. In contrast to astroglial cultures, LPS induction of NOS activity in RAW 264.7 macrophage cells was not affected by NE or dibutyryl cyclic AMP. These results indicate that in brain, inducible NOS in astrocytes can be regulated by neurotransmitter binding to glial receptors.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682604     DOI: 10.1111/j.1471-4159.1993.tb13425.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  26 in total

1.  Potentiation of cytokine induced iNOS expression in the human intestinal epithelial cell line, DLD-1, by cyclic AMP.

Authors:  M Cavicchi; B J Whittle
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

Review 2.  Receptor-mediated interaction between the sympathetic nervous system and immune system in inflammation.

Authors:  G Haskó
Journal:  Neurochem Res       Date:  2001-09       Impact factor: 3.996

3.  Isoproterenol regulates tumour necrosis factor, interleukin-10, interleukin-6 and nitric oxide production and protects against the development of vascular hyporeactivity in endotoxaemia.

Authors:  C Szabó; G Haskó; B Zingarelli; Z H Németh; A L Salzman; V Kvetan; S M Pastores; E S Vizi
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

4.  Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis.

Authors:  Paul E Polak; Sergey Kalinin; Douglas L Feinstein
Journal:  Brain       Date:  2011-02-04       Impact factor: 13.501

5.  Eicosanoids and nitric oxide influence induction of reactive gliosis from spreading depression in microglia but not astrocytes.

Authors:  A O Caggiano; R P Kraig
Journal:  J Comp Neurol       Date:  1996-05-20       Impact factor: 3.215

Review 6.  White-matter astrocytes, axonal energy metabolism, and axonal degeneration in multiple sclerosis.

Authors:  Melissa Cambron; Miguel D'Haeseleer; Guy Laureys; Ralph Clinckers; Jan Debruyne; Jacques De Keyser
Journal:  J Cereb Blood Flow Metab       Date:  2012-01-04       Impact factor: 6.200

7.  The noradrenaline precursor L-DOPS reduces pathology in a mouse model of Alzheimer's disease.

Authors:  Sergey Kalinin; Paul E Polak; Shao Xia Lin; Amul J Sakharkar; Subhash C Pandey; Douglas L Feinstein
Journal:  Neurobiol Aging       Date:  2011-06-25       Impact factor: 4.673

Review 8.  Noradrenergic Modulation on Dopaminergic Neurons.

Authors:  Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2018-03-23       Impact factor: 3.911

9.  Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-kappaB binding to DNA.

Authors:  S K Park; H L Lin; S Murphy
Journal:  Biochem J       Date:  1997-03-01       Impact factor: 3.857

Review 10.  Intrinsic regulation of brain inflammatory responses.

Authors:  Elena Galea; Michael T Heneka; Cinzia Dello Russo; Douglas L Feinstein
Journal:  Cell Mol Neurobiol       Date:  2003-10       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.